Novo signs $1.4B macrocyclic peptide pact with Danish biotech
The cardiometabolic deal extends Novo's push beyond injectable incretins into macrocycle chemistry.
TR
By Tom Reyes · Markets Editor
Sep 17 06:56 ETSource: Fierce Biotech
The wire
- 01Novo Nordisk entered a cardiometabolic collaboration worth up to $1.4 billion with a Danish biotech to explore macrocyclic peptides, Fierce Biotech reported.
- 02Macrocycles are a route toward oral and more drug-like peptides, an area large pharma is buying into as incretin competition intensifies.
- 03Deal terms are largely milestone-based, and no clinical candidate or timeline has been detailed.
From the source
Read at fiercebiotech.comNovo explores macrocycles’ potential in $1.4B cardiometabolic pact with Danish biotech